Compare Amgen, Inc. (AMGN) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Cipher Mining Inc — how do they compare? Amgen, Inc. trades at $416.97 (market cap $224.14B), while Cipher Mining Inc trades at $17.97 (market cap $7.14B). The key difference: Amgen, Inc. is far larger — about 31.4× Cipher Mining Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| AMGN | CIFR | |
|---|---|---|
Market Cap | $224.14B | $7.14B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $29.18 |
52-Week Low | $271.18 | $4.72 |
Enterprise Value | $267.45B | $11.90B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
CIFR trades at $17.74, up 8.63% in the last session, but remains in a bearish technical trend with key support at $16. The company is transitioning from Bitcoin mining to AI data centers, reporting a Q2 2026 loss per share of $0.65, missing estimates. Revenue was $224 million in 2025 but fell to $191 million in 2026, with a net loss widening to $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target.
The outlook hinges on successful execution of its AI infrastructure pivot, offering growth potential but carrying high risk due to persistent losses, heavy capital expenditure, and reliance on project financing. Investors face volatility from operational cash burn and competitive pressures in the data center market, warranting caution despite optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
